The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of Deucravacitinib in pediatric participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort. Part A will evaluate the drug levels of BMS-986165 to enable selection of 2 dose levels to be studied in Part B. Part B will assess the efficacy and safety of two dose levels in pediatric participants with moderate to severe plaque psoriasis. The 5-year long-term extension (LTE) period will observe the long-term safety and tolerability of deucravacitinib in pediatric participants with psoriasis who have completed Parts A or B of the study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Geometric mean observed average concentration at steady state (Cavg.ss) for deucravacitinib at Week 2
Timeframe: Week 2
Maximum observed plasma concentration at steady state (Cmax.ss) for deucravacitinib at Week 2
Timeframe: Week 2
Trough observed plasma concentration (Ctrough) for deucravacitinib at Week 2
Timeframe: Week 2
Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16
Timeframe: Week 16
Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16
Timeframe: Week 16
Incidence of Adverse Events (AEs)
Timeframe: Up to 316 weeks
Incidence of serious adverse events (SAEs)
Timeframe: Up to 316 weeks
Monitoring of growth: Body weight
BMS Study Connect Contact Center www.BMSStudyConnect.com
Timeframe: Up to 316 weeks
Monitoring of growth: Height
Timeframe: Up to 316 weeks
Monitoring of growth: Tanner staging (sexual maturation)
Timeframe: Up to 316 weeks